Antibacterial polymer for selectively removing gram-negative bacteria as well as preparation method and application of antibacterial polymer

By designing fluorine-containing amphiphilic antibacterial polymer PDmHFn, using the characteristics of DMAEMA and HFBMA, combined with RAFT polymerization method, the problem that existing antibacterial polymers cannot selectively eliminate Gram-negative bacteria is solved, and multiple drug-resistant ESKAPE is achieved Gram-negative bacteria have high efficiency killing and reduced resistance.

CN119081028AActive Publication Date: 2024-12-06NORTHWESTERN POLYTECHNICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411099555.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-12-06
Estimated Expiration
2044-08-12

AI Technical Summary

Technical Problem

Existing antibacterial polymers cannot effectively selectively remove Gram-negative bacteria, and are prone to inducing bacterial resistance, resulting in weakening of therapeutic effects.

Method used

Design a fluorine-containing amphiphilic antibacterial polymer PDmHFn. By optimizing the molecular weight, monomer arrangement, charge and hydrophilic ratio of the polymer, DMAEMA and HFBMA are used as cationic and hydrophobic monomers, combined with RAFT polymerization method, to achieve the preparation of the Selective clearance of Gram-negative bacteria.

Benefits of technology

This antibacterial polymer can effectively kill multiple drug-resistant ESKAPE Gram-negative bacteria, which is lower than the minimum antibacterial concentration of existing antibiotics and does not cause drug resistance, providing a new drug for treating Gram-negative bacteria infection. choose.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081028A_ABST
    Figure CN119081028A_ABST
Patent Text Reader

Abstract

The invention provides an antibacterial polymer for selectively removing gram-negative bacteria as well as a preparation method and application of the antibacterial polymer, and solves the problem that an existing antibacterial polymer with multiple advantages still cannot specifically and effectively remove gram-negative bacteria. The chemical formula of the antibacterial polymer is PDmHFn, an amine-containing monomer 2-(dimethylamino) ethyl methacrylate (DMAEMA) is used as a cation block unit, a fluorine-containing monomer 2, 2, 3, 3, 4, 4, 4-heptafluorobutyl methacrylate (HFBMA) is used as a hydrophobic group block unit, the ratio of n to m represents the molar ratio of the monomers HFBMA to DMAEMA, and n / m is larger than or equal to 0.1 and smaller than or equal to 0.2.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedical engineering materials, and in particular relates to an antibacterial polymer for selectively removing Gram-negative bacteria, and a preparation method and application thereof. Background Art

[0002] With the excessive and irrational use of antibiotics, the speed at which bacteria develop resistance to antibiotics has accelerated. In recent years, the rapid spread of multidrug-resistant (MDR) bacteria has evolved into a global medical crisis. A group of two Gram-positive bacteria (E. faecalis, S. aureus) and four Gram-negative bacteria (K. pneumoniae, A. baumannii, P. aeruginosa, Enterobacter species) are known as the notorious ESKAPE pathogens, which are of particular concern because they can "escape" antibiotic treatment and show high incidence of drug resistance. However, the development of new antibiotics lags far behind the speed at which bacteria develop resistance. There are currently some new antibiotics undergoing clinical trials that have shown potential in eliminating Gram-positive bacteria; but no new antibiotic class has been approved for the treatment of Gram-negative bacterial infections in more than 50 years.

[0003] Carbapenem-resistant Gram-negative ESKAPE bacteria and extended-spectrum β-lactamase (ESBL) K.pneumonia and Enterobacter species have been listed by the World Health Organization as a priority list of pathogens that require urgent treatment in 2023; these resistant Gram-negative ESKAPE pathogens can cause serious nosocomial infections such as pneumonia, surgical site infections, urinary tract infections, bloodstream infections, etc. In intensive care units in the United States, these Gram-negative bacterial infections account for 70%, and similar reports have appeared in other parts of the world. Therefore, humans urgently need to develop new antimicrobial agents that are not prone to drug resistance to deal with MDR Gram-negative ESKAPE bacterial infections.

[0004] In recent years, antimicrobial peptides, with the help of their cationic amphiphilicity in structural characteristics, exert their bactericidal activity through membrane perturbation, electrostatic and hydrophobic interactions. As a new type of antimicrobial agent that is not easy to induce bacterial resistance, it has gradually attracted the attention of more and more researchers. However, antimicrobial peptides cannot be widely used due to their complex production and purification process, high production cost, difficulty in mass production, and easy decomposition and loss of activity. Therefore, antimicrobial polymers with multiple advantages such as low cost, large-scale production, easy synthesis and controllable structure have emerged, which are expected to replace antimicrobial peptides as a new generation of antimicrobial agents. However, the antimicrobial polymers that have been studied so far still focus on broad-spectrum bacteria. While killing pathogenic bacteria, they also indiscriminately kill other bacteria, resulting in widespread bacterial resistance, greatly weakening the therapeutic effect of drugs, and seriously threatening people's lives and health. Compared with Gram-positive bacterial infections, Gram-negative bacteria are more difficult to treat due to their complex cell wall structure and highly active efflux pump system. Therefore, the development of new antibacterial drugs that can selectively kill Gram-negative bacteria can effectively prevent the abuse of antibiotics and slow down the development of bacterial resistance, which is of great significance for the treatment of Gram-negative bacterial infections.

[0005] To this end, the research team of the present invention has developed an antibacterial polymer that can selectively eliminate Gram-negative bacteria. Summary of the invention

[0006] The purpose of the present invention is to solve the deficiency that the existing antibacterial polymers with multiple advantages are still unable to specifically and effectively eliminate Gram-negative bacteria, and to provide an antibacterial polymer for selectively eliminating Gram-negative bacteria and a preparation method and application thereof; the antibacterial polymer can not only selectively eliminate Gram-negative bacteria, but also delay the development of drug resistance.

[0007] To achieve the above purpose, the technical solution provided by the present invention is:

[0008] An antibacterial polymer, the special thing is that the chemical formula is PD m HF n , the structural formula is as follows:

[0009]

[0010] The polymer uses amine-containing monomer 2-(dimethylamino)ethyl methacrylate (DMAEMA) as a cationic block unit and fluorine-containing monomer 2,2,3,3,4,4,4-heptafluorobutyl methacrylate (HFBMA) as a hydrophobic group block unit, wherein the ratio of n to m represents the molar ratio of the monomers HFBMA and DMAEMA, and 0.1≤n / m≤0.2.

[0011] Furthermore, its chemical formula is PD45 HF 5 Under this ratio, the antibacterial polymer has a better effect in removing Gram-negative bacteria.

[0012] The present invention also provides a method for preparing the antibacterial polymer, which is characterized in that it comprises the following steps:

[0013] 1) Dissolve the initiator, chain transfer agent, DMAEMA and HFBMA in an organic solvent, add them into a Schlenk reaction tube, and stir to completely dissolve them;

[0014] 2) subjecting the reaction system of step 1) to at least three double-row pipe freeze-pump-fill cycles to replace the atmosphere with an inert gas;

[0015] 3) placing the reaction system of step 2) in a constant temperature stirring environment to carry out the reaction;

[0016] 4) After the reaction in step 3) is completed, the reaction product is precipitated and vacuum dried to obtain the target antibacterial polymer, i.e., the fluorinated amphiphilic block copolymer PD m HF n .

[0017] The above preparation method is briefly as follows: monomers DMAEMA and HFBMA are synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization, and then the reaction product is precipitated and vacuum dried to obtain the target product PD m HF n .

[0018] Further, in step 1), the initiator is azobisisobutyronitrile, dimethyl azobisisobutyrate, benzoyl peroxide or tert-butyl perbenzoate;

[0019] The chain transfer agent is 4-cyanopentanoic acid dithiobenzoic acid, dithiobenzoic acid cyanoisopropyl ester or 2-[dodecylthio(thiocarbonyl)thio]-2-methylpropionic acid;

[0020] The organic solvent is dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or dioxane.

[0021] Furthermore, in step 1), the molar ratio of the initiator, the chain transfer agent, DMAEMA and HFBMA is 1:10:400:100-1:10:450:50, wherein the total concentration of the two monomers is 1 mmol / L.

[0022] Furthermore, in step 2), the inert gas is nitrogen or argon.

[0023] Furthermore, in step 3), a thermostatic agitator is used, the reaction temperature is 50-70° C., and the reaction time is 18-24 h.

[0024] Furthermore, in step 4), the reaction product is precipitated by a poor solvent, where the poor solvent is a solvent that cannot dissolve the antibacterial polymer, such as n-hexane, petroleum ether, n-pentane, etc.

[0025] In addition, the present invention also provides the use of the above antibacterial polymer in selectively removing Gram-negative bacteria, and an antibacterial agent for removing Gram-negative bacteria based on the application, wherein the active ingredient is the above antibacterial polymer PD m HF n .

[0026] Concept and principle of the present invention:

[0027] In view of the problem that the current antibacterial polymer lacks Gram selectivity, the present invention studies the structure-activity relationship of the antibacterial polymer and finds that it can be achieved by optimizing the molecular weight of the polymer, the arrangement of the monomers, the charge carried by the polymer, the side groups and the hydrophilic-hydrophobic ratio. It is also found that balancing the ratio of cationic and hydrophobic units in the antibacterial polymer structure is also very important for obtaining high antibacterial activity and low toxicity (hemolysis and cytotoxicity). It can be seen that positive charge and hydrophilicity are important factors affecting the biomedical properties of antibacterial polymers. Therefore, how to reasonably select cationic monomers and hydrophobic monomers and adjust the ratio of the two is the key to designing new antibacterial polymers. Unlike Gram-positive bacteria, lipopolysaccharide (LPS) as a unique component of the outer membrane of Gram-negative bacteria can become a target for Gram selection. In this way, if an antibacterial polymer capable of killing Gram-negative bacteria is to be developed, the key is also the selection of cationic monomers and hydrophobic monomers and the ratio of the two.

[0028] For this reason, the present invention screens cationic monomers and hydrophobic monomers. The hydrophobic part of the current antibacterial polymer is usually various types of aliphatic (cyclic, linear and branched) and aromatic groups, but the present invention finds that the fluorine-containing group has more superior hydrophobicity and oleophobicity during the research process, which plays an important role in cell membrane penetration and can play a more efficient membrane destruction antibacterial mechanism. Fluorine-containing polymers show lower cytotoxicity and hemolytic activity at the same time, but there is no document showing the antibacterial effect of fluorine-containing amphiphilic polymers at present. Therefore, in combination with the bacterial membrane destruction mechanism, based on its superior hydrophobicity and oleophobicity, the present invention's research team intends to use fluorine-containing groups as hydrophobic monomers to enhance antibacterial ability. At the same time, in the screening process, the present invention finds that amine-containing cationic monomer 2-(dimethylamino) ethyl methacrylate DMAEMA has a specific affinity for the LPS of Gram-negative bacteria, so the present invention's research team intends to use DMAEMA as a cationic monomer. Using DMAEMA and HFBMA as cationic monomers and hydrophobic monomers to synthesize fluorine-containing amphiphilic polymers, and its antibacterial ability is verified.

[0029] The advantages of the present invention are:

[0030] 1. Based on the dual synergistic effect of HFBMA's efficient membrane destruction mechanism and DMAEMA's LPS-specific affinity, this invention designs a new antibacterial polymer, fluorinated amphiphilic polymer PD m HF n This type of antibacterial polymer exerts its antibacterial effect through a membrane destruction mechanism, and its MIC against multidrug-resistant Gram-negative pathogens in ESKAPE can be as low as 4μg / mL, which is better than the current first-line antibiotics. After it continuously treated E.coli ESBL for 110 generations, it did not show drug resistance. Therefore, this fluorinated amphiphilic polymer can effectively selectively kill multidrug-resistant Gram-negative bacteria while reducing the probability of drug resistance. The fluorinated amphiphilic polymer designed by the present invention will fill the gap in the current drugs for treating Gram-negative bacterial infections.

[0031] 2. The present invention adopts the RAFT polymerization method to polymerize the monomers DMAEMA and HFBMA into a fluorinated amphiphilic block copolymer, which has a simple preparation process, low cost, can be mass-produced and has a controllable structure; the fluorinated monomer introduced therein has more superior hydrophobicity and oleophobicity, which can enhance the antibacterial ability of the polymer, and the amine-containing monomer introduced therein has a specific affinity for Gram-negative bacteria LPS; it further proves that the regulation of positive charge and hydrophilicity can give the antibacterial polymer Gram selectivity, which provides a new idea for the development of new antibacterial drugs with low drug resistance and strong killing effect to combat Gram-negative bacterial infection, and can effectively broaden the drug spectrum for targeted elimination of Gram-negative bacteria. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 Fluorinated amphiphilic polymer PD m HF n Molecular structure diagram.

[0033] Figure 2 Fluorinated amphiphilic polymer PA m HF n Molecular structure diagram.

[0034] Figure 3 The cytotoxicity results of Example 1 and Comparative Example 5 are shown in FIG.

[0035] Figure 4 The morphology of bacteria after treatment in Example 1 and Comparative Examples 2, 3, and 5 is shown.

[0036] Figure 5 It is the drug resistance result diagram of Example 1 and Comparative Example 5.

[0037] Figure 6 This is a graph showing the LPS inhibition test results of Example 1. DETAILED DESCRIPTION

[0038] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments:

[0039] Embodiment 1:

[0040] like Figure 1 As shown, the method for preparing the antibacterial polymer comprises the following steps:

[0041] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid, DMAEMA and HFBMA in 4 mL of dioxane at a molar ratio of 1:10:450:50, wherein the total concentration of the two monomers is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0042] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0043] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 60° C., and reacting for 24 hours;

[0044] 4) The reaction product of step 3) is precipitated with n-hexane and vacuum dried to obtain a light pink solid, which is the fluorinated amphiphilic polymer PD 45 HF 5 .

[0045] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by the minimum inhibitory concentration (MIC) test. 45HF 5 The MICs of multidrug-resistant ESKAPE were >512, >512, 64, 4, 4, and 4 μg / mL, respectively. 45 HF 5 It showed almost no antibacterial activity against Gram-positive bacteria, but had a strong killing effect on Gram-negative bacteria. 45 HF 5 It has obvious selective antibacterial effect on Gram-negative bacteria.

[0046] Embodiment 2:

[0047] like Figure 1 As shown, the method for preparing the antibacterial polymer comprises the following steps:

[0048] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid, DMAEMA and HFBMA in 4 mL of dioxane at a molar ratio of 1:10:400:100, wherein the total concentration of the two monomers is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0049] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0050] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 60° C., and reacting for 24 hours;

[0051] 4) The reaction product of step 3) is precipitated with n-hexane and vacuum dried to obtain a light pink solid, which is the fluorinated amphiphilic polymer PD. 40 HF 10 .

[0052] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by MIC test. 40 HF 10 For multidrug-resistant ESKAPE, the MICs were >512, >512, 256, 16, 8, and 8 μg / mL, respectively. 40 HF 10 It showed almost no antibacterial activity against Gram-positive bacteria, but under this ratio, relative to Example 1, its antibacterial effect against Gram-negative bacteria gradually weakened, but still showed Gram-selective antibacterial ability.

[0053] It can be seen from the MIC of Example 1 and Example 2 that the fluorinated amphiphilic polymer PD m HF nIt can selectively eliminate Gram-negative bacteria and shows almost no antibacterial activity against Gram-positive bacteria; when the fluoride content is too high, its antibacterial effect against Gram-negative bacteria is weakened.

[0054] Comparative Example 1:

[0055] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid, DMAEMA and HFBMA in 4 mL of dioxane at a molar ratio of 1:10:350:150, wherein the total concentration of the two monomers is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0056] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0057] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 60° C., and reacting for 24 hours;

[0058] 4) The reaction product of step 3) is precipitated with n-hexane and vacuum dried to obtain a light pink solid, which is the fluorinated amphiphilic polymer PD. 35 HF 15 .

[0059] PD 35 HF 15 It showed poor water solubility at a room temperature pH of around 7.4, so its MIC for multidrug-resistant ESKAPE could not be further tested; it can be seen that the regulation of the ratio of cationic monomers to hydrophobic monomers is particularly important.

[0060] Comparative Example 2:

[0061] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid and DMAEMA in 4 mL of dioxane at a molar ratio of 1:10:500, wherein the monomer concentration is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0062] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0063] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 60° C., and reacting for 24 hours;

[0064] 4) The reaction product of step 3) was precipitated with n-hexane and vacuum dried to obtain a light pink solid amphiphilic polymer PD 50 .

[0065] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by MIC test. 50 The MICs of multidrug-resistant ESKAPE were >512, >512, 256, 8, 64, and 16 μg / mL, respectively. 50 It shows almost no antibacterial activity against Gram-positive bacteria, but has a certain clearance effect on Gram-negative bacteria.

[0066] Compared with Example 1-2, it can be seen that PD 50 It also exhibits the ability to selectively remove Gram-negative bacteria, but its removal effect is weaker than that of Examples 1 and 2, and is not sufficient to support its practical application. This further highlights the importance of fluorinated monomers. Fluorinated monomers have more superior hydrophobicity and oleophobicity, play an important role in cell membrane penetration, and can improve antibacterial ability to a certain extent, which in turn confirms the necessity of the fluorinated amphiphilicity of the present invention.

[0067] Comparative Example 3:

[0068] 1) Azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid and BocAEMA were dissolved in 4 mL of dioxane at a molar ratio of 1:10:500, wherein the monomer concentration was 1 mmol / L, and added into a Schlenk reaction tube, and stirred to completely dissolve;

[0069] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0070] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 65° C., and reacting for 24 hours;

[0071] 4) the reaction product of step 3) is precipitated with n-hexane and dried under vacuum;

[0072] 5) The reaction product of step 4) was dissolved in 2 mL of 4 mol HCl / dioxane system and reacted for 12 h for deprotection to obtain a light pink solid amphiphilic polymer PA 50 .

[0073] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by MIC test. 50 The MICs for multidrug-resistant ESKAPE were 32, 32, >512, 256, 64, and 256 μg / mL, respectively.

[0074] Compared with Examples 1-2 and Comparative Example 2, it can be seen that PA 50It has a broad spectrum and can eliminate Gram-positive bacteria and some Gram-negative bacteria at the same time. Its ability to eliminate Gram-positive bacteria is significantly better than that to eliminate Gram-negative bacteria. Therefore, it does not have the ability to selectively eliminate Gram-negative bacteria. It can be seen that the function of selectively eliminating Gram-negative bacteria is mainly derived from the contribution of the monomer DMAEMA. Using it as a cationic block unit can give the antibacterial polymer the function of selectively eliminating Gram-negative bacteria.

[0075] Comparative Example 4:

[0076] like Figure 2 As shown, the method for preparing the antibacterial polymer comprises the following steps:

[0077] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid, BocAEMA and HFBMA in 4 mL of dioxane at a molar ratio of 1:10:450:50, wherein the total concentration of the two monomers is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0078] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0079] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 65° C., and reacting for 24 hours;

[0080] 4) the reaction product of step 3) is precipitated with n-hexane and dried under vacuum;

[0081] 5) The reaction product of step 4) was dissolved in 2 mL of 4 mol HCl / dioxane system and reacted for 12 h for deprotection to obtain a light pink solid amphiphilic polymer PA 45 HF 5 .

[0082] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by MIC test. 45 HF 5 The MICs for multidrug-resistant ESKAPE were 32, 16, 256, 256, 32, and 256 μg / mL, respectively.

[0083] Compared with Examples 1-2 and Comparative Example 3, it can be seen that PA 45 HF 5 It also does not have the ability to selectively eliminate Gram-negative bacteria, but with the addition of fluorinated hydrophobic monomers in the hydrophobic part, the effect of eliminating Gram-positive bacteria is significantly improved, which once again confirms that fluorinated hydrophobic monomers have the ability to enhance the antibacterial effect.

[0084] Comparative Example 5:

[0085] like Figure 1 As shown, the method for preparing the antibacterial polymer comprises the following steps:

[0086] 1) Dissolve azobisisobutyronitrile, 4-cyanovaleryl dithiobenzoic acid, BocAEMA and HFBMA in 4 mL of dioxane at a molar ratio of 1:10:400:100, wherein the total concentration of the two monomers is 1 mmol / L, and add them into a Schlenk reaction tube, stirring to completely dissolve them;

[0087] 2) The reaction system of step 1) is subjected to at least three double-row pipe freeze-pump-fill cycles, and the atmosphere is replaced with an argon atmosphere;

[0088] 3) placing the reaction system of step 2) in a thermostatic stirrer, slowly heating to 65° C., and reacting for 24 hours;

[0089] 4) the reaction product of step 3) is precipitated with n-hexane and dried under vacuum;

[0090] 5) The reaction product of step 4) was dissolved in 2 mL of 4 mol HCl / dioxane system and reacted for 12 h for deprotection to obtain a light pink solid amphiphilic polymer PA 40 HF 10 .

[0091] The antibacterial properties of the polymer against multidrug-resistant ESKAPE were characterized by MIC test. 40 HF 10 The MICs for multidrug-resistant ESKAPE were 32, 16, 64, 32, 32, and 64 μg / mL, respectively.

[0092] Compared with Comparative Example 4, it can be seen that as the fluorine content increases, the antibacterial ability of the antibacterial polymer can be significantly improved, but its ability to remove Gram-negative bacteria is still limited and has no selectivity for Gram-negative bacteria.

[0093] In summary, by comparing Examples 1-2, Comparative Example 2 and Comparative Example 3-4, it was found that the polymers introduced with the monomer DMAEMA in Examples 1-2 and Comparative Example 2 selectively sterilized Gram-negative bacteria, while Comparative Example 3-4 exhibited a broad-spectrum antibacterial effect and had no ability to remove Gram-negative bacteria.

[0094] Figure 3The cell compatibility results of Example 1 and Comparative Example 5 show that at 64 and 128 μg / mL, Comparative Example 5 shows no cytotoxicity in a short period of time, and shows slight cytotoxicity after long-term co-culture; Example 1 shows no cytotoxicity at 64 and 128 μg / mL, and also has a slight effect of promoting cell proliferation. This shows that the antibacterial polymer prepared by the present invention has good biocompatibility.

[0095] Figure 4 The scanning electron microscope images of Example 1, Comparative Examples 2-3 and Comparative Example 5 after co-incubation with bacteria. After being treated with the polymer, wrinkles, depressions and even perforations appeared on the surface of each bacterium to varying degrees. Compared with Comparative Examples 2 and 3, respectively, Example 1 and Comparative Example 5 showed that the polymers introduced with fluorinated hydrophobic monomers had stronger membrane destruction ability. The surfaces of bacteria treated with these polymers almost all showed serious perforations. Some bacteria were even broken and no obvious bacterial morphology could be observed, which confirmed that they had significant membrane destruction antibacterial mechanism.

[0096] Figure 5 The results of drug resistance test of Example 1 and Comparative Example 5 are shown. After 110 generations of continuous treatment with 0.5×MIC levofloxacin (Lev), Example 1 and Comparative Example 5, the MIC of E. coli ESBL treated with Lev increased by 16 times, while Example 1 and Comparative Example 5, although slightly fluctuated, did not cause a significant increase in MIC. Therefore, the probability of Example 1 and Comparative Example 5 inducing bacterial resistance is extremely low, and it can be considered that they will hardly induce bacterial resistance, due to their significant membrane-destructive antibacterial mechanism.

[0097] Figure 6 The results of the LPS inhibition test of Example 1 are shown in Figure 1. The co-incubation of LPS with Example 1 significantly affects the antibacterial effect of the polymer in a concentration-dependent manner. Even at a concentration lower than 1 μg / mL, LPS can increase the MIC of Example 1 against E. coli ESBL by two times. After the LPS concentration is gradually increased to 25 μg / mL, the antibacterial effect of Example 1 E. coli ESBL gradually weakens to 8×MIC. Therefore, it can be inferred that Example 1 has a certain affinity with LPS on the surface of Gram-negative bacteria.

[0098] Of course, during the research process, the present invention also adjusted the initiator, chain transfer agent, organic solvent, poor solvent, and even the reaction temperature and reaction time within the aforementioned limited range, and the target antibacterial polymer that meets the purpose of the invention can be obtained, and it can also efficiently select and remove Gram-negative bacteria, and reduce the probability of drug resistance, without affecting the performance of the target product. In order to facilitate core comparison and minimize the influencing factors, the same initiator, chain transfer agent, organic solvent, poor solvent, and even reaction temperature and reaction time are used for the aforementioned embodiments and comparative examples.

[0099] The present invention believes that, based on the same antibacterial mechanism, if the hydrophobic monomer 2,2,3,3,4,4,4-heptafluorobutyl methacrylate is replaced with other fluorine-containing groups having the same methacrylate structure, such as 2,2,2-trifluoroethyl methacrylate, 2,2,3,3,3-pentafluoropropyl methacrylate, etc., an antibacterial polymer with the same selective ability to eliminate Gram-negative bacteria can also be synthesized.

[0100] In summary, the fluorinated amphiphilic polymer prepared by the present invention based on LPS-specific affinity and efficient membrane-breaking mechanism has precise Gram-selective antibacterial ability, low probability of drug resistance and good biocompatibility, and therefore has broad application prospects.

[0101] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can easily think of various equivalent modifications or substitutions within the technical scope disclosed in the present invention, and these modifications or substitutions should be included in the protection scope of the present invention.

Claims

1. An antibacterial polymer, characterized in that The chemical formula is PD m HF n , the structural formula is as follows: Herein, the ratio of n to m represents the molar ratio of the monomers 2,2,3,3,4,4,4-heptafluorobutyl methacrylate and 2-(dimethylamino)ethyl methacrylate, and 0.1≤n / m≤0.

2.

2. The antibacterial polymer according to claim 1, characterized in that: Its chemical formula is PD 45 HF5.

3. The method for preparing the antibacterial polymer according to claim 1, characterized in that: The following steps are involved: 1) dissolving an initiator, a chain transfer agent, 2-(dimethylamino)ethyl methacrylate and 2,2,3,3,4,4,4-heptafluorobutyl methacrylate in an organic solvent, adding the mixture into a Schlenk reaction tube, and stirring the mixture to completely dissolve the mixture; 2) subjecting the reaction system of step 1) to at least three double-row pipe freeze-pump-fill cycles to replace the atmosphere with an inert gas; 3) placing the reaction system of step 2) in a constant temperature stirring environment to carry out the reaction; 4) After the reaction in step 3) is completed, the reaction product is precipitated and vacuum dried to obtain the target antibacterial polymer.

4. The method for preparing the antibacterial polymer according to claim 3, characterized in that: In step 1), the initiator is azobisisobutyronitrile, dimethyl azobisisobutyrate, benzoyl peroxide or tert-butyl perbenzoate; The chain transfer agent is 4-cyanopentanoic acid dithiobenzoic acid, dithiobenzoic acid cyanoisopropyl ester or 2-[dodecylthio(thiocarbonyl)thio]-2-methylpropionic acid; The organic solvent is dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile or dioxane.

5. The method for preparing the antibacterial polymer according to claim 3, characterized in that: In step 1), the molar ratio of the initiator, the chain transfer agent, 2-(dimethylamino)ethyl methacrylate and 2,2,3,3,4,4,4-heptafluorobutyl methacrylate is 1:10:400:100-1:10:450:50, wherein the total molar concentration of the two monomers is 1 mmol / L.

6. The method for preparing the antibacterial polymer according to any one of claims 3 to 5, characterized in that: In step 2), the inert gas is nitrogen or argon.

7. The method for preparing the antibacterial polymer according to claim 6, characterized in that: In step 3), a thermostatic agitator is used, the reaction temperature is 50-70° C., and the reaction time is 18-24 h.

8. The method for preparing the antibacterial polymer according to claim 7, characterized in that: In step 4), the reaction product is precipitated by a poor solvent.

9. Use of the antimicrobial polymer according to claim 1 in selectively eliminating Gram-negative bacteria.

10. An antibacterial agent for removing Gram-negative bacteria, characterized in that: The active ingredient is the antibacterial polymer described in claim 1.

Citation Information

Patent Citations

  • Alkylaminoalkyl oligomers as broad-spectrum antimicrobial agent

    CN103619359A

  • Cation-zwitterion block copolymer

    CN110804144A